The 2023 Essential Diagnostics List (EDL), an evidence-based registry of in vitro diagnostics (IVDs) that helps countries make diagnostic decisions at the national level, was recently announced by the World Health Organization (WHO).
There are two firsts in this year's list:
The inclusion of three hepatitis E virus (HEV) tests, one of which is a rapid test to help detect and monitor HEV infection; and a recommendation to add personal glucose monitoring devices to current medical guidelines for diabetes.

●Two new tests have been included for endocrine disorders: 17-hydroxyprogesterone was included as a point-of-care test to diagnose and follow up congenital adrenal hyperplasia outside the neonatal period, and parathyroid hormone was included as a point-of-care test to help evaluate the causes of calcium homeostasis disorders and monitor the effects of treatment;

●Two tests for reproductive, maternal and neonatal health should be included: a point-of-care test for blood grouping and rhesus factor in relation to maternal health care and haemolytic disorders of the foetus and newborn, and the Kleihauer-Betke acid-elution test as a general IVD for use in clinical laboratories to aid in the diagnosis and management of fetomaternal haemorrhage;

●For cardiovascular health, the inclusion of high-sensitivity troponin I and T to aid in the diagnosis of acute myocardial infarction in healthcare facilities with clinical laboratories.